Oral small molecule GLP-1 receptor agonist
Danuglipron tablet
DANU_PO
Doses in this pooled treatment
- Danuglipron 200 mg oral twice daily
- Danuglipron 80 mg oral twice daily
- Danuglipron 140 mg tablet twice daily
- Danuglipron 40 mg oral twice daily
- Danuglipron 120 mg oral twice daily
- Danuglipron 160 mg oral twice daily
- Danuglipron 2.5 mg tablet twice daily
- Danuglipron 10 mg tablet twice daily
- Danuglipron 3 mg tablet
- Danuglipron 10 mg tablet
- Danuglipron 30 mg tablet
- Danuglipron 100 mg tablet
- Danuglipron 300 mg tablet
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.33 (0.00 to 25.32) | 0.47 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.52 (0.52 to 107) | 0.33 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 7.07 (1.00 to 101) | 0.13 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.88 (0.43 to 14.22) | 0.27 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.60 (0.99 to 7.70) | 0.29 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 10.41 (3.05 to 48.38) | 0.07 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 25.04 (4.36 to 347) | 0.05 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.79 (1.18 to 18.10) | 0.17 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 8.01 (0.75 to 227) | 0.18 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 1.15 (0.05 to 49.28) | 0.43 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.62 (0.04 to 10.34) | 0.46 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.63 (0.47 to 133) | 0.24 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 22.12 (3.15 to 384) | 0.07 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.74 (2.39 to 36.56) | 0.22 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.92 (1.29 to 50.98) | 0.43 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.17 (0.92 to 35.06) | 0.24 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.32 (0.34 to 7.94) | 0.61 |
Trials
- NCT04707313A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY2021 · 628 randomized · 26 weeks
- NCT03985293A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE2020 · 412 randomized · 16 weeks
- NCT04552470AN 8-WEEK PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TWICE DAILY PF-06882961 ADMINISTRATION IN JAPANESE ADULTS WITH TYPE 2 DIABETES MELLITUS2020 · 37 randomized · 8 weeks